A PHASE 2, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS
Latest Information Update: 01 Feb 2023
At a glance
- Drugs PF 06760805 (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 16 Oct 2020 Status changed from not yet recruiting to completed.
- 14 Feb 2020 New trial record